Cover of Clinical Review Report: Icosapent Ethyl (Vascepa)

Clinical Review Report: Icosapent Ethyl (Vascepa)

(HLS Therapeutics Inc.)

Indication: Prevention of cardiovascular events in statin-treated patients

CADTH Common Drug Review

Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.
Read

The objective of the current review is to perform a systematic review of the beneficial and harmful effects of icosapent ethyl for the indication.